A statement from APDA in this time of unrest

All of us at the American Parkinson Disease Association (APDA) support equality for all and reject racism.  Our programs...see more are open to everyone and we foster a safe and welcoming place for all to join us, whether virtually or in person.  Disparities and injustice exist on many levels, including within the healthcare system. At APDA, […]

Read More

New medication approved by FDA for OFF symptoms

Kynmobi Sunovion Pharmaceuticals announced that the Food and Drug Administration (FDA) approved Kynmobi® (apomorphine hydrochloride), a new sublingual medication...see more for fast relief of OFF symptoms of Parkinson’s disease (PD). Apomorphine acts as a dopamine agonist, mimicking the effects of dopamine in the brain. It was previously only available as Apokyn, an injectable medication that provides […]

Read More

New drug approved for OFF episodes

Today, Neurocrine Biosciences announced that the Food and Drug Administration (FDA) approved ONGENTYS ® (opicapone), a new medication for...see more treatment of Parkinson’s disease (PD). Opicapone is a catechol-O-methyltransferase (COMT) inhibitor to be used once-daily as an add-on treatment to levodopa for patients who are experiencing OFF time with their current medication regimen. Opicapone is in […]

Read More

CORONAVIRUS DISEASE 2019 AND THE PD COMMUNITY

APDA COVID-19 INFORMATION & RESOURCES: The American Parkinson Disease Association (APDA) continues to monitor the COVID-19 situation, particularly as...see more it relates to our Parkinson’s disease (PD) community. This page is updated regularly as new information becomes available. Vaccines: Three COVID-19 vaccines have been approved for use in the United States — one manufactured by Pfizer/BioNTech, […]

Read More

Taking Parkinson’s education to the farmers market: educating under-served communities

Dr. Lynda Nwabuobi, Movement Disorder Fellow at Columbia Presbyterian...see more Medical Center in New York City, attended APDA’s Diversity in Parkinson’s Disease (PD) Research Conference in May and was inspired. Dr. Nwabuobi  had just spent the day learning about health care disparities in PD care, low […]

Read More

New medication, Istradefylline, gets approved for Parkinson’s disease

On August 27, 2019, pharmaceutical company Kyowa Kirin received FDA approval...see more for Istradefylline, a new medication for Parkinson’s disease (PD) to be used as an add-on treatment to carbidopa/levodopa for those experiencing OFF episodes. (For more information on OFF periods in PD, please see this recent APDA […]

Read More